EZH2 and glioblastoma: EZH2 and/or PRC2 have been the focus for targeted inhibition due to their documented altered activity and levels in several tumor types including prostate, glioblastoma, B-cell lymphoma and multiple myeloma [77,78] and the suggestion that the associated H3K27me3 profile may confer stemness properties not only in human embryonic stem cells, but also in cancer cells.